Research
Read how they describe their research on their University of British Columbia profile.
Latest papers
Mechanistic modeling of time-dependent antibody clearance in multiple myeloma: A physiologically based pharmacokinetic model of isatuximab.
Journal of pharmaceutical sciences · 2026 · senior author
Albumin Levels Are Predictive of Cachexia-Induced Time-Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab.
CPT: pharmacometrics & systems pharmacology · 2026 · senior author
A multicompartment stomach physiologically-based pharmacokinetic model capturing gastric reacidification can improve food effect predictions of weak bases.
Journal of pharmaceutical sciences · 2026 · senior author
24 publications.
Mechanistic modeling of time-dependent antibody clearance in multiple myeloma: A physiologically based pharmacokinetic model of isatuximab.
Proctor JR, Wong H
Albumin Levels Are Predictive of Cachexia-Induced Time-Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab.
Proctor JR, Wong H
A multicompartment stomach physiologically-based pharmacokinetic model capturing gastric reacidification can improve food effect predictions of weak bases.
Cheng L, Chiang PC, Wright MR, Wong H
Clinical study design strategies to mitigate confounding effects of time-dependent clearance on dose optimization of therapeutic antibodies.
Proctor JR, Wong H
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.
Moein A, Jin JY, Wright MR, Wong H
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor).
Moein A, Jin JY, Wright MR, Wong H
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.
Lee HM, Muhammad N, Lieu EL, Cai F, Mu J, Ha YS, Cao G, Suchors C, Joves K, Chronis C, Li K, Ducker GS, Olszewski K, Cai L, Allison DB, Bachert SE, Ewing WR, Wong H, Seo H, Kim IY, Faubert B, Kim J, Kim J
Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor.
Moein A, Jin JY, Wright MR, Alicke B, Wong H
Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: A comprehensive review of the current literature.
Proctor JR, Wong H
Chemically engineering the drug release rate of a PEG-paclitaxel conjugate using click and steric hindrance chemistries for optimal efficacy.
Nguyen A, Chao PH, Ong CY, Rouhollahi E, Fayez NA, Lin L, Brown JI, Böttger R, Page B, Wong H, Li SD
Frequent collaborators
- Shyh-Dar Li and Brent Page: 1 shared paper
- Shyh-Dar Li and Harvey Wong: 1 shared paper
- Brent Page and Harvey Wong: 1 shared paper
- Pharmsci
- Faculty of Pharmaceutical Sciences
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 27, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.